Ascendis Pharma A/S - ADR

Ascendis Pharma A/S - ADR

ASND

Get informed when a big investor buys or sells

+ Follow
Market Cap$15.86B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ascendis Pharma A/S - ADRAscendis Pharma A/S - ADR27-104%17.61.8
$311.00

Target Price by Analysts

26.3% upsideAscendis Pharma A/S Target Price DetailsTarget Price
$158.03

Current Fair Value

35.8% downside

Overvalued by 35.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$15.86 Billion
Enterprise Value$16.19 Billion
Dividend Yield$- (-)
Earnings per Share$-3.62
Beta0.36
Outstanding Shares61,681,886

Return

Return on Equity103.71%ROE
Return on Assets25.26%
Return on Invested Capital-2.77%

Valuation & Multiples

P/E Ratio26.98P/E Ratio
PEG-3.48PEG
Price to Sales17.59Price to Sales
Price to Book Ratio35.18Price to Book Ratio
Enterprise Value to Revenue18.67
Enterprise Value to EBIT-665.36
Enterprise Value to Net Income31
Total Debt to Enterprise0.06
Debt to Equity1.85Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 13, 2026
EPS Estimate
$1.71
Average shareholder expectation
Revenue Estimate
$376.75 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 11, 2026
EPS Estimate
$1.56
Average shareholder expectation
Revenue Estimate
$467.97 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3650▲ 20.22%
Total Calls38,900▼ 96.94%
Total Puts14,200▼ 93.14%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %12.91%▼ 75.79%
Total Invested$2.12B▼ 83.02%
Investors Holding111▼ 179.00%

ESG Score

No data

About Ascendis Pharma A/S

CEO: Jan Moeller Mikkelsen